BridgeBio Pharma stock presents new cardiac data for BBP-418 trial
Published on 10/05/2026 at 19:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BridgeBio Pharma (ISIN US10806X1028) was trading at USD 66.54 on Nasdaq on October 5, 2026, down 1.06 percent at 1:14 p.m. ET. The company presented new 12-month cardiac data for BBP-418 from the Phase 3 FORTIFY trial, with 100 percent of treated participants with elevated troponin I reaching the normal range versus 40 percent on placebo, according to StockTitan on October 5, 2026.
BBP-418 shows cardiac signals
The cardiac findings add a new dimension to the commercial and regulatory case for BBP-418, an investigational oral therapy for LGMD2I/R9. At Month 12, 54 percent of treated participants had stable or improved left ventricular ejection fraction, compared with 25 percent in the placebo group, while the high-sensitivity troponin I difference favored treatment by 17.8 ng/L.
The company said the treatment met all primary and secondary endpoints at the prespecified 12-month interim analysis. The release also states that BBP-418 is under FDA Priority Review with a target action date of November 27, 2026, giving the program a clearly defined regulatory checkpoint.
Revenue growth meets a loss
BridgeBio's Q2 2026 revenue reached USD 243.7 million, up 120 percent year over year and above the USD 222.6 million consensus estimate, while diluted EPS was negative USD 0.78 versus a consensus loss of USD 0.64, according to Yahoo Finance. The comparison matters because commercial growth is accelerating even as profitability remains negative.
Analyst support remains higher than the share price alone suggests. StockAnalysis lists a Buy consensus from 22 analysts and an average 12-month price target of USD 109.10, while Investing.com reported that TD Cowen reiterated a Buy rating with a USD 110.00 target on October 5, 2026.
Stock sits below yearly high
BridgeBio Pharma stock was trading at USD 66.54 on Nasdaq on October 5, 2026, with a 52-week range of USD 52.75 to USD 93.42 and market capitalization of USD 13.0 billion. The share price stood 28.8 percent below the 52-week high, keeping the BBP-418 regulatory decision and upcoming earnings report central to the valuation debate.
BridgeBio Pharma stock details
- Company: BridgeBio Pharma, Inc.
- ISIN: US10806X1028
- Ticker: BBIO
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 1:14 p.m. ET): USD 66.54
- Market capitalization: USD 13.0 billion (as of October 5, 2026)
- 52-week range: USD 52.75-93.42 (as of October 5, 2026)
- Sector / Industry: Health Care / Biotechnology
Upcoming dates for BridgeBio Pharma stock
- October 28, 2026: Q3 2026 results after the market close, with a conference call at 4:30 p.m. ET
- November 27, 2026: FDA PDUFA target action date for BBP-418
